Loading clinical trials...
Loading clinical trials...
Effect of Tetrabenazine on Stroop Interference in Huntington Disease
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Terence Cardinal Cooke Health Care Center
New York, New York, United States
Start Date
March 1, 2013
Primary Completion Date
January 1, 2018
Completion Date
January 1, 2018
Last Updated
May 28, 2025
2
ACTUAL participants
Tetrabenazine withdrawal
DRUG
Lead Sponsor
New York Medical College
NCT04012411
NCT06414967
NCT05822908
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions